PDE4B-IN-2

Cat. No.:	HY-115687
CAS No.:	915082-52-9
Molecular Formula:	$C_{19}H_{18}ClN_3O_2S$
Molecular Weight:	387.88
Target:	Phosphodiesterase (PDE)
Pathway:	Metabolic Enzyme/Protease
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 25 mg/mL (64.45 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.5781 mL	12.8906 mL	25.7812 mL
	5 mM	0.5156 mL	2.5781 mL	5.1562 mL
	10 mM	0.2578 mL	1.2891 mL	2.5781 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

PDE4B-IN-2 is an orally active and selective PDE4B inhibitor with an IC_{50} of 15 nM. PDE4B-IN-2 inhibits PDE4D (IC_{50}=1.7 μM). PDE4B-IN-2 exhibits potent anti-inflammatory effects[1].

IC_{50} & Target

PDE4B	PDE4D
15 nM (IC_{50})	1.7 μM (IC_{50})

In Vitro

PDE4B-IN-2 (compound 33) does not inhibit CYP1A2, CYP3A4, CYP2C9, and CYP2D (IC_{50}>10 μM)[1].

PDE4B-IN-2 inhibits LPS-induced TNF-aproduction in vitro from mouseperipheral blood mononuclear cell (PBMC; IC_{50}=0.5 M)[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

PDE4B-IN-2 (compound 33; 2 mg/kg; po) has a C_{max} of 8.7 μg/mL and an AUC of 52.3 μg•h/mL in mice[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Kenji Naganuma, et al. Discovery of selective PDE4B inhibitors. Bioorg Med Chem Lett. 2009 Jun 15;19(12):3174-6.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA